During the corresponding time, Zymeworks Inc saw a revenue deteriorated by -90.58 % year on year, sequentially revenue grew by 90.61 %. While revenue at the Zymeworks Inc 's corporate clients
Zymeworks Inc. Poised to Reveal Robust Q3 2024 Financial Results Amid Positive Market Performance As the frequencies of innovation and adaptation reverberate throughout the biotechnology sector, Zymeworks Inc. (Nasdaq: ZYME), a beacon of clinical-stage biotechnological advancement, is preparing once again to demonstrate its financial acumen and strategic progression. Based in Vancouver, British Columbia, Zymeworks has steadfastly pursued the elevation of therapeutic paradigms through its development of novel, multifunctional biotherapeutics designed specifically to address the challenges presented by diseases that defy conventional treatment protocols.On October 31, 2024, Zymeworks will unveil its financial ...
Zymeworks Inc., a clinical-stage biotechnology company dedicated to enhancing the standard of care for challenging diseases, has achieved a significant milestone with the clearance of its investigational new drug (IND) application for ZW191 by the United States Food and Drug Administration (FDA). ZW191, the company s ground-breaking folate receptor-targeted topoisomerase I inhibitor (TOPO1i) antibody-drug conjugate (ADC), shows promising potential for effectively treating difficult-to-treat diseases. This development marks a substantial step forward in precision medicine and holds immense implications for Zymeworks and the wider medical community.Key Facts:1. Zymeworks IND application for ZW191, an innovati...
Zymeworks Achieves Key Milestones in Global Development: NMPA Acceptance of BLA for Zanidatamab in China and Inclusion in Nasdaq Biotechnology Index VANCOUVER, British Columbia, June 10, 2024 Zymeworks Inc. (Nasdaq: ZYME), a pioneering clinical-stage biotechnology company, is making significant strides in advancing its robust pipeline of cutting-edge biotherapeutics aimed at enhancing the treatment of challenging diseases. Recently, the company announced a major accomplishment as the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China has accepted the Biologics License Application (BLA) for zanidatamab. This innovative therapy is intended for the second-line trea...
Zymeworks Inc., a leading biopharmaceutical company, is currently under investigation by Pomerantz Law Firm following alleged claims made by investors. This article aims to provide an in-depth analysis of the potential consequences and implications for Zymeworks amidst the ongoing investigation. Investors and stakeholders are advised to closely monitor these developments and consider their implications for the company s future prospects.Investigation Details:Pomerantz LLP, a renowned law firm specializing in securities litigation, has initiated an investigation into Zymeworks Inc. based on allegations raised by concerned investors. The investigation focuses on potential violations of federal securities laws,...
The pharmaceutical industry is witnessing a rapid advancement in the development of innovative biotherapeutics to tackle challenging diseases. Zymeworks Inc., a pioneering biotechnology company, has recently announced the acceptance of five abstracts for poster presentations at the prestigious American Association for Cancer Research (AACR) Annual Meeting. This event, scheduled to take place from April 5-10, 2024, at the San Diego Convention Center in California, promises to be a platform for Zymeworks to unveil its groundbreaking preclinical data on antibody-drug conjugate (ADC) and multispecific platforms. This article delves into the significance of Zymeworks cutting-edge research and its potential impli...
In a recent update, Zymeworks Inc., a clinical-stage biotechnology company, has outlined its strategic priorities for 2024 and 2025. This forward-thinking approach aims to revolutionize the standard of care for challenging-to-treat diseases through the development of novel, multifunctional biotherapeutics. Let s delve into the details and assess the potential impact of these strategies on the company.Zymeworks primary focus in 2024 and 2025 lies in its commitment to advancing its diverse pipeline of innovative biotherapeutics. By emphasizing research and development, the company aims to address significant unmet medical needs and positively impact patient outcomes. Zymeworks dedication to improving the sta...
Sources:
Zymeworks Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Zymeworks Inc’s corporate clients.
For your research, we’ve provided 9 tables on Zymeworks Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
24.75 %